NCT07549464
Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 3 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Oct 1, 2026 to Aug 20, 2026
- Site details revised
- Notable Eligibility criteria expanded, about 24 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year
Arms and interventions
Dose Escalation of PLM-102Experimental
Treatment will be adminstered on an outpatient basis
Drugs: PLM-102
Sites
1 site in 1 country
- UT MD AndersonHouston, Texas, United States